JP2002515223A5 - - Google Patents

Download PDF

Info

Publication number
JP2002515223A5
JP2002515223A5 JP2000543623A JP2000543623A JP2002515223A5 JP 2002515223 A5 JP2002515223 A5 JP 2002515223A5 JP 2000543623 A JP2000543623 A JP 2000543623A JP 2000543623 A JP2000543623 A JP 2000543623A JP 2002515223 A5 JP2002515223 A5 JP 2002515223A5
Authority
JP
Japan
Prior art keywords
polypeptide
composition
polynucleotide
mek3
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000543623A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002515223A (ja
Filing date
Publication date
Priority claimed from US09/060,410 external-priority patent/US6165461A/en
Application filed filed Critical
Publication of JP2002515223A publication Critical patent/JP2002515223A/ja
Publication of JP2002515223A5 publication Critical patent/JP2002515223A5/ja
Pending legal-status Critical Current

Links

JP2000543623A 1998-04-14 1999-04-14 Taoプロテインキナーゼおよびその使用方法 Pending JP2002515223A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/060,410 US6165461A (en) 1998-04-14 1998-04-14 Tao protein kinases and methods of use therefor
US09/060,410 1998-04-14
PCT/US1999/008165 WO1999053076A1 (en) 1998-04-14 1999-04-14 Tao protein kinases and methods of use therefor

Publications (2)

Publication Number Publication Date
JP2002515223A JP2002515223A (ja) 2002-05-28
JP2002515223A5 true JP2002515223A5 (https=) 2006-06-08

Family

ID=22029289

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000543623A Pending JP2002515223A (ja) 1998-04-14 1999-04-14 Taoプロテインキナーゼおよびその使用方法

Country Status (8)

Country Link
US (2) US6165461A (https=)
EP (1) EP1071787A1 (https=)
JP (1) JP2002515223A (https=)
CN (1) CN100374568C (https=)
AU (1) AU758731B2 (https=)
BR (1) BR9909679A (https=)
CA (1) CA2325824A1 (https=)
WO (1) WO1999053076A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6165461A (en) 1998-04-14 2000-12-26 Board Of Regents, University Of Texas System Tao protein kinases and methods of use therefor
US7078182B1 (en) 1998-04-14 2006-07-18 Board Of Regents, The University Of Texas System TAO protein kinase polypeptides and methods of use therefor
US7148330B2 (en) * 1999-07-30 2006-12-12 Schering Corporation Binding compounds for IL-27
EP1409656A4 (en) * 2001-03-12 2005-01-12 Darley Pharmaceuticals Ltd SCREENING OF PHEROMONAL COMPOUNDS OF NON-STEROID AND NON-PEPTIDE INVERTEBRATE HAVING ACTIVITY MODULATING MITOGEN-ACTIVATED PROTEIN KINASE
US6806293B1 (en) * 2001-03-12 2004-10-19 Darley Pharmaceuticals Ltd Use of pheromone compounds having MAP kinase modulating activity
WO2002099044A2 (en) * 2001-06-05 2002-12-12 Exelixis, Inc. B3galts as modifiers of the p53 pathway and methods of use
AU2002324598A1 (en) * 2001-08-06 2003-02-24 Exelixis, Inc. Trps as modifiers of the p53 pathway and methods of use
WO2003051905A2 (en) * 2001-12-13 2003-06-26 Exelixis, Inc. Taojiks as modifiers of the beta-catenin pathway and methods of use
WO2004012817A2 (en) * 2002-07-31 2004-02-12 Kylix B.V. Use of genes identified to be involved in tumor development for the development of anti-cancer drugs
US7282479B2 (en) * 2003-03-31 2007-10-16 Ttc Co., Ltd. Hyperthermia agent for malignant tumor comprising cytokine and magnetic fine particles
EP1514558A1 (en) * 2003-09-15 2005-03-16 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Use of MARKK or MARKK antagonists for the treatment of pathologies characterised by increased or reduced phosphorylation of MARK or tau protein
US20100122354A1 (en) * 2005-06-20 2010-05-13 Exelixis, Inc. Cdc6s as modifiers of the pten/akt pathway and methods of use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4326097A (en) * 1996-07-03 1998-01-21 Chiron Corporation (mitogen-activated protein kinase) kinase-3 (mkk3) interacting protein (mip)
AU8296698A (en) * 1997-07-08 1999-02-08 Cadus Pharmaceutical Corporation (kds) protein kinase molecules and uses related thereto
US6165461A (en) 1998-04-14 2000-12-26 Board Of Regents, University Of Texas System Tao protein kinases and methods of use therefor

Similar Documents

Publication Publication Date Title
ES2443042T3 (es) LTBP2 como biomarcador, diana terapéutica y diagnóstica
Fu The superfamily of arginine/serine-rich splicing factors
JP2002515223A5 (https=)
Bellan et al. Candidate biomarkers of liver fibrosis: a concise, pathophysiology-oriented review
WO2004076639B1 (en) Use of gene expression profiling in the diagnosis and treatment of lupus nephritis and systemic lupus erythematosus
CA2273821A1 (en) Detection and modulation of the iaps and naip for the diagnosis and treatment of proliferative disease
KR20070058577A (ko) 직장결장암의 초기 발견을 위한 의약 스크리닝 및 분자적진단 테스트: 그들의 시약, 방법 및 키트
Garbers et al. Cytokines of the interleukin-6 family as emerging targets in inflammatory bowel disease
WO2021075536A1 (ja) 幹細胞遊走剤を使用した糖尿病治療
WO2003078456A2 (en) Human diabetes-mediating proteins
US20030118579A1 (en) Sparc-related proteins
Yip et al. Dipeptidyl Peptidase-4 deficiency effectively protects the brain and neurological function in rodent after acute Hemorrhagic Stroke
JP2008506949A (ja) 肥満、糖尿病およびインスリン抵抗性の診断および治療の方法
US20010036625A1 (en) Method for identifying compounds for treatment of insulin resistance
WO2007141004A1 (en) Use of adipsin (adn) as a therapeutic or diagnostic target
JP2006507801A (ja) 糖尿病の治療および診断のための方法および組成物
USRE40624E1 (en) Compositions and methods of using apoptosis signaling kinase related kinase (ASKRK)
JPWO2005019472A1 (ja) シノビオリン活性調節作用の検出方法
JP2005534319A5 (https=)
JP2005529603A (ja) 糖尿病を予防、治療、および診断するための組成物および方法
Chen et al. Association analysis of the variant in the regulatory subunit of phosphoinositide 3‐kinase (p85α) with Type 2 diabetes mellitus and hypertension in the Chinese Han population
US20060074018A1 (en) Methods of diagnosing & treating diabetes and insulin resistance
CA2448265C (en) Methods and compounds for the diagnosis of inflammatory disease and identification of pharmacological agents
KR970707155A (ko) 사람 스탄니오칼신-알파(Human stanniocalcin-alpha)
CN101780268A (zh) 用于诊断,预防和治疗胰岛素抵抗的方法和试剂